GC WellBeing
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
GC WellBeing makes injectable vitamins, minerals, and specialty prescription drugs, such as a human placenta extract and a tissue-regenerating pain-relief injection, that clinics and hospitals administer directly to patients.
It also supplies a clinic-exclusive line of oral health supplements, including vitamins and probiotics, under the Dr.PNT brand, as well as aesthetic medical devices such as skin boosters and fillers. Listed on KOSDAQ, Korea's tech and small-cap board, its prescription injectable nutrition products form the core of its business, with clinics and pharmaceutical wholesalers as its primary distribution channels.
Summary is AI-generated and may contain errors · figures from DART filings
GC WellBeing in five facts
What does GC WellBeing do?
GC WellBeing makes injectable vitamins, minerals, and specialty prescription drugs, such as a human placenta extract and a tissue-regenerating pain-relief injection, that clinics and hospitals administer directly to patients.
Where is GC WellBeing listed and in which sector?
GC WellBeing (Korean name: 녹십자웰빙) trades under KRX code 234690 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is GC WellBeing?
Its market capitalisation was US$147.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were GC WellBeing's latest annual revenue and operating profit?
For fiscal year 2025, GC WellBeing reported revenue of US$124.3M, operating profit of US$13.1M and net income of US$7.6M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 23.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingSep 14
- [Amended] Operating results (consolidated) (preliminary) (fair disclosure)
GC WellBeing updated its previously filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$36.7M (+33.8% year on year), operating profit of US$3.26M (+9.6% year on year) and net income of US$2.79M (+1060.4% year on year).
Earnings · Jul 31 · 2 versions - Operating results (consolidated) (preliminary) (fair disclosure)
GC WellBeing filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$33.8M (+41.3% year on year), operating profit of US$3.32M (−3.3% year on year) and a net loss of US$2.09M (from a profit a year earlier).
Earnings · May 7 - Change of largest shareholderOwnership change · Mar 31
- Cash/in-kind dividend decision
GC WellBeing declared a cash dividend of US$0.10 per share.
Dividend · Feb 9 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 26